Antibody Validation for Cell Signaling

Antibodies from cell signaling have been indicated before [49 (link), 50 (link)]. Other antibodies included anti-SRGAP1 antibody (1:1000, sc-81939, Santa Cruz Biotechnology, Dallas, TX, USA), RhoA (#05-778), Cdc42 (#05-542), Rac1 (#05-389), N-cadherin (33-3900, Invitrogen), and Vimentin (YM3158, ImmunoWay Biotechnology Company, Plano, TX, USA). The secondary antibodies were in line with that in our earlier work [49 (link)].

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Huang T., Zhou Y., Zhang J., Wong C.C., Li W., Kwan J.S., Yang R., Chan A.K., Dong Y., Wu F., Zhang B., Cheung A.H., Wu W.K., Cheng A.S., Yu J., Wong N., Kang W, & To K.F. (2017). SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. Oncogene, 37(9), 1159-1174.

Publication 2017

sc-81939 Cdc42 N-cadherin Vimentin

Anti antibody Antibodies Cdc42 N cadherin Rhoa Vimentin

Corresponding Organization :

Other organizations : Prince of Wales Hospital, Chinese University of Hong Kong, Nanjing Drum Tower Hospital, Chinese University of Hong Kong, Shenzhen

Top 5 similar protocols

Protocol cited in 1 other protocol

Variable analysis

independent variables

Anti-SRGAP1 antibody (1:1000, sc-81939, Santa Cruz Biotechnology, Dallas, TX, USA)
RhoA (#05-778)
Cdc42 (#05-542)
Rac1 (#05-389)
N-cadherin (33-3900, Invitrogen)
Vimentin (YM3158, ImmunoWay Biotechnology Company, Plano, TX, USA)

dependent variables

Not explicitly mentioned

control variables

Antibodies from cell signaling indicated before [49 (link), 50 (link)]
Secondary antibodies in line with that in our earlier work [49 (link)]

controls

Positive control: Antibodies from cell signaling indicated before [49 (link), 50 (link)]
Negative control: Secondary antibodies in line with that in our earlier work [49 (link)]

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!